Recent SEC filings
Insider and ownership filing tracker
Form 4 reports insider transactions. Schedule 13D and 13G filings report certain significant ownership positions. 13F reports institutional holdings when filed by an investment manager. Always open the original filing for context.
Company and financial overview
This is a data-generated overview, not a published Rithvik Chethan research rating. Figures use the latest usable company filing and may differ from vendor-calculated trailing metrics.
Financial performance charts
Annual values from SEC filings. Free cash flow is calculated as operating cash flow less capital expenditures.
Upcoming catalyst timeline
Review the Earnings tab for the expected date and estimates.
PRIMARY DOCUMENT
EMA, RSI, MACD, volume, structure, and key levels update after a completed daily candle.
How the research score works
The overall score is a weighted research judgment covering business quality, fundamental strength, growth catalysts, valuation, technical condition, and downside risk. A high score does not eliminate risk, and a low score does not guarantee poor performance.
Company overview
Regeneron Pharmaceuticals is a biotechnology company best known for Eylea, a leading treatment for age related macular degeneration and other eye diseases, alongside a growing pipeline in immunology, oncology, and other therapeutic areas.
Business model
Regeneron earns substantial revenue from Eylea, along with growing contributions from Dupixent, an immunology drug developed in partnership with Sanofi, and an expanding pipeline of internally developed and licensed therapies.
Growth drivers
- Dupixent continued indication expansion and international growth
- New pipeline product launches across oncology and other areas
- Eylea high dose formulation supporting continued franchise relevance
- Antibody discovery platform driving future pipeline candidates
Competitive position
Regeneron's scientific research capabilities and antibody discovery platform have produced multiple successful drugs, giving it a strong foundation for continued pipeline development even as its legacy Eylea franchise faces biosimilar competition.
Risks
Biosimilar competition for Eylea represents a meaningful near term revenue headwind, pipeline execution needs to succeed to offset that pressure, and dependence on partnership economics with Sanofi for Dupixent creates some revenue sharing complexity.
Valuation
Regeneron trades at a moderate multiple reflecting the biosimilar competition overhang on its Eylea franchise, balanced against continued Dupixent growth and pipeline potential.
Final view
Regeneron's Dupixent growth and pipeline diversification provide a path through Eylea biosimilar competition, though execution risk remains. My view is neutral, with Dupixent growth trajectory being the most important thing to track.
Overall rating: 68/100
This website and its analysis are provided for educational and informational purposes only. Nothing on this site constitutes financial, investment, legal, or tax advice, or an offer to buy or sell any security. Market data is provided by Finnhub and other third-party sources and may be delayed, incomplete, or inaccurate. The author may hold positions in securities discussed, and opinions may change without notice. Past performance does not guarantee future results. Always conduct your own research and consult a qualified financial professional before making investment decisions.